"Observational Study to Assess Intravitreal Aflibercept Injections Used in a Treat and Extend Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients"

CompletedOBSERVATIONAL
Enrollment

163

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

November 9, 2018

Study Completion Date

November 27, 2018

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY